PASSReviewer 1· 80% conf
Trial registration, methods, limitations, and funding/COI are well reported; the main gaps are no CONSORT checklist reference and deferral of some secondary outcomes.
Evidence
direct quote[Abstract and Methods]
“Trial registration ClinicalTrials.gov NCT04585581”direct quote[Methods, Secondary outcome measures]
“Here we report the main secondary maternal cardiometabolic outcomes and will report the remaining secondary outcomes in separate publications.”paraphrase[Discussion, Strengths and limitations]
“Most participants were well educated, potentially resulting in healthy volunteer bias... Most of our participants were also white and so it is difficult to generalise our findings to other ethnicities.”PASSReviewer 2· 75% conf
Methods are detailed, the trial is registered, limitations and funding/COI are thoroughly reported, and conclusions are proportional; however, no reporting guideline (e.g., CONSORT) is referenced and some secondary outcomes are deferred to later publications.
Evidence
paraphrase[Methods, Study design]
“The trial was registered in ClinicalTrials.gov ( NCT04585581 ) on 25 September 2020.”direct quote[Methods, Secondary outcome measures]
“Here we report the main secondary maternal cardiometabolic outcomes and will report the remaining secondary outcomes in separate publications.”paraphrase[Funding / Competing interests]
“The trial was funded by the Novo Nordisk Foundation (NNF19SA058975), the Liaison Committee for education, research, and innovation in Central Norway, and the Joint Research Committee between St Olav's Hospital and the Faculty of Medicine and Health Sciences, NTNU (FFU).”